8 assets in Dyskeratosis Congenita

Therapeutic assets addressing Dyskeratosis Congenita, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Nivestim Dyskeratosis Congenita	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2	B (57)
Alemtuzumab Dyskeratosis Congenita	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2	CCC (53)
Busulfanum Dyskeratosis Congenita	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Cyclophosphamide Dyskeratosis Congenita	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2	CCC (53)
Fludarabine Dyskeratosis Congenita	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2	CCC (53)
Melphalan Dyskeratosis Congenita	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2	CCC (53)
Rituximab Dyskeratosis Congenita	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Tacrolimus Dyskeratosis Congenita	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2	CCC (53)